An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Completed

Conditions studied: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

In brief

This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.

Key facts

Study ID

NCT00229658

Run by

AstraZeneca

People needed

1297

Starts

2005-09-01

Expected to finish

2008-05-01

Last updated by the study team

2015-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The following inclusion criteria are consistent with information in the SYMLIN package insert and apply to insulin using patients with type 2 or type 1 diabetes who:
• Have failed to achieve the desired or optimal level of glycemic control despite utilizing appropriate, individualized insulin regimens
• Have A1C <=9.0% within 3 months of study enrollment
• Are receiving ongoing diabetes care under the guidance of a Health Care Provider (HCP) trained in the use of SYMLIN

You may not qualify if…

• The following exclusion criteria are consistent with the SYMLIN package insert and specifically exclude patients who:
• Are poorly compliant with their current insulin regimen, as defined by their HCP
• Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
• Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
• Have hypoglycemia unawareness
• Have a confirmed diagnosis of gastroparesis
• Require the use of drugs that stimulate gastrointestinal motility
• Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
• Have been treated with SYMLIN within 3 months prior to study start

Where it is running

• Research Site — Montgomery, Alabama, United States
• Research Site — Tucson, Arizona, United States
• Research Site — Anaheim, California, United States
• Research Site — Encinitas, California, United States
• Research Site — Escondido, California, United States
• Research Site — Fresno, California, United States
• Research Site — Lafayette, California, United States
• Research Site — Moreno Valley, California, United States
• Research Site — Sacramento, California, United States
• Research Site — Salinas, California, United States
• Research Site — Santa Barbara, California, United States
• Research Site — Torrance, California, United States
• Research Site — Vacaville, California, United States
• Research Site — Arvada, Colorado, United States
• Research Site — Aurora, Colorado, United States
• Research Site — Norwalk, Connecticut, United States
• Research Site — Wilmington, Delaware, United States
• Research Site — Hialeah, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Maitland, Florida, United States
• Research Site — Melbourne, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Plantation, Florida, United States
• Research Site — Tallahassee, Florida, United States
• Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.